NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, blocking the transfer of cholesteryl esters from HDL to LDL particles, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Obicetrapib's Promise | NewAmsterdam Pharma's lead drug candidate shows potential to revolutionize cardiovascular disease treatment, with significant LDL-C reduction and MACE benefits |
Market Opportunity | Analysts project potential U.S. sales exceeding $1.3 billion, with global end-user sales opportunity surpassing $2.5 billion for obicetrapi |
Patent Protection | Robust patent portfolio expected to provide market exclusivity until late 2030s, ensuring long-term revenue potential for NewAmsterdam Pharma |
Analyst Outlook | Price targets range from $29.03 to $52.39, reflecting optimism in obicetrapib's potential despite challenges in regulatory approval and market adoption |
Metrics to compare | NAMS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNAMSPeersSector | |
---|---|---|---|---|
P/E Ratio | −10.8x | −1.5x | −0.6x | |
PEG Ratio | 0.56 | 0.04 | 0.00 | |
Price/Book | 3.4x | 1.9x | 2.6x | |
Price / LTM Sales | 57.1x | 17.9x | 3.0x | |
Upside (Analyst Target) | 92.8% | 320.4% | 51.6% | |
Fair Value Upside | Unlock | 21.9% | 9.3% | Unlock |